KR101944124B1 - 약학 조성물 - Google Patents

약학 조성물 Download PDF

Info

Publication number
KR101944124B1
KR101944124B1 KR1020137013466A KR20137013466A KR101944124B1 KR 101944124 B1 KR101944124 B1 KR 101944124B1 KR 1020137013466 A KR1020137013466 A KR 1020137013466A KR 20137013466 A KR20137013466 A KR 20137013466A KR 101944124 B1 KR101944124 B1 KR 101944124B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
patient
composition according
prodrug
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137013466A
Other languages
English (en)
Korean (ko)
Other versions
KR20140033314A (ko
Inventor
단핑 리
Original Assignee
멜린타 서브시디어리 코프.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 멜린타 서브시디어리 코프. filed Critical 멜린타 서브시디어리 코프.
Publication of KR20140033314A publication Critical patent/KR20140033314A/ko
Application granted granted Critical
Publication of KR101944124B1 publication Critical patent/KR101944124B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137013466A 2010-11-24 2011-11-21 약학 조성물 Expired - Fee Related KR101944124B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41680710P 2010-11-24 2010-11-24
US61/416,807 2010-11-24
PCT/US2011/061643 WO2012071324A2 (en) 2010-11-24 2011-11-21 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
KR20140033314A KR20140033314A (ko) 2014-03-18
KR101944124B1 true KR101944124B1 (ko) 2019-01-30

Family

ID=46146374

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137013466A Expired - Fee Related KR101944124B1 (ko) 2010-11-24 2011-11-21 약학 조성물

Country Status (21)

Country Link
US (2) US20140088164A1 (enExample)
EP (1) EP2642996B1 (enExample)
JP (2) JP6370550B2 (enExample)
KR (1) KR101944124B1 (enExample)
CN (1) CN103391778B (enExample)
AU (1) AU2011332031B2 (enExample)
BR (1) BR112013012833A8 (enExample)
CA (1) CA2818249C (enExample)
EA (1) EA027791B1 (enExample)
ES (1) ES2836809T3 (enExample)
HU (1) HUE052801T2 (enExample)
IL (1) IL226378A0 (enExample)
MX (1) MX350565B (enExample)
MY (2) MY171941A (enExample)
NZ (1) NZ610638A (enExample)
PH (1) PH12013501069A1 (enExample)
PT (1) PT2642996T (enExample)
SG (2) SG10201509530YA (enExample)
UA (1) UA113722C2 (enExample)
WO (1) WO2012071324A2 (enExample)
ZA (1) ZA201303732B (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046992A1 (en) 2000-03-22 2001-11-29 Batts Donald Herman Treatment of urinary tract infections with antibacterial oxazolidinones
JP2003527424A (ja) 2000-03-22 2003-09-16 ファルマシア・アンド・アップジョン・カンパニー オキサゾリジノン錠剤製剤
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
US20100227903A1 (en) * 2006-02-09 2010-09-09 Merck & Co., Inc. Polymer Formulations of CETP Inhibitors

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
AR028253A1 (es) * 2000-03-16 2003-04-30 Pfizer Prod Inc Inhibidores de la glucogeno fosforilasa
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
NZ580951A (en) * 2005-04-29 2011-06-30 Cubist Pharm Inc Therapeutic compositions
EP1912730A2 (en) 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
EP1909763A2 (en) 2005-07-28 2008-04-16 Isp Investments Inc. Benzoquinones of enhanced bioavailability
UY30535A1 (es) * 2006-08-10 2008-03-31 Cipla Ltd Composicion comprendiendo farmacos antirretrovirales y al menos un polimero insoluble en agua, proceso de preparacion y aplicaciones.
US20120208857A1 (en) * 2009-10-13 2012-08-16 Burak Eric S Pharmaceutical Compositions
WO2011159626A1 (en) * 2010-06-14 2011-12-22 Bend Research, Inc. Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
WO2012061360A2 (en) * 2010-11-01 2012-05-10 Rib-X Pharmaceuticals, Inc. Pharmaceutical compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010046992A1 (en) 2000-03-22 2001-11-29 Batts Donald Herman Treatment of urinary tract infections with antibacterial oxazolidinones
JP2003527424A (ja) 2000-03-22 2003-09-16 ファルマシア・アンド・アップジョン・カンパニー オキサゾリジノン錠剤製剤
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
US20100227903A1 (en) * 2006-02-09 2010-09-09 Merck & Co., Inc. Polymer Formulations of CETP Inhibitors

Also Published As

Publication number Publication date
ES2836809T3 (es) 2021-06-28
JP6370550B2 (ja) 2018-08-08
HUE052801T2 (hu) 2021-05-28
MX350565B (es) 2017-09-11
US20160374995A1 (en) 2016-12-29
BR112013012833A8 (pt) 2018-01-02
CN103391778B (zh) 2016-04-20
EP2642996A4 (en) 2014-05-21
MY171941A (en) 2019-11-08
ZA201303732B (en) 2018-12-19
MY182136A (en) 2021-01-18
NZ610638A (en) 2015-05-29
PT2642996T (pt) 2020-12-30
AU2011332031A1 (en) 2013-06-06
WO2012071324A3 (en) 2012-08-16
KR20140033314A (ko) 2014-03-18
EP2642996B1 (en) 2020-09-23
WO2012071324A2 (en) 2012-05-31
MX2013005813A (es) 2013-09-13
BR112013012833A2 (pt) 2016-08-23
CA2818249A1 (en) 2012-05-31
CA2818249C (en) 2021-04-13
SG190354A1 (en) 2013-06-28
JP2013543893A (ja) 2013-12-09
EA201390764A1 (ru) 2013-09-30
US20140088164A1 (en) 2014-03-27
PH12013501069A1 (en) 2013-07-08
SG10201509530YA (en) 2015-12-30
UA113722C2 (uk) 2017-03-10
CN103391778A (zh) 2013-11-13
IL226378A0 (en) 2013-07-31
EA027791B1 (ru) 2017-09-29
JP2017081950A (ja) 2017-05-18
US10300046B2 (en) 2019-05-28
EP2642996A2 (en) 2013-10-02
AU2011332031B2 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
JP2017141285A (ja) 薬学的組成物
KR20140022773A (ko) 약학 조성물
US20200237744A1 (en) Antimicrobial Compositions with Effervescent Agents
KR20140033314A (ko) 약학 조성물
HK1230972A1 (en) Pharmaceutical compositions comprising radezolid
HK1230972A (en) Pharmaceutical compositions comprising radezolid
HK40020067A (en) Antimicrobial compositions with effervescent agents
HK40020067B (en) Antimicrobial compositions with effervescent agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220125

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220125